Tiziana Life Sciences has filed a patent for a method of treating and preventing symptoms of coronavirus infections using antibodies that recognize CD3. The patent also includes details on routes of administration and formulations for the treatment. GlobalData’s report on Tiziana Life Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Tiziana Life Sciences, Cancer treatment biomarkers was a key innovation area identified from patents. Tiziana Life Sciences's grant share as of September 2023 was 14%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment and prevention of coronavirus using anti-cd3 antibodies
A recently filed patent (Publication Number: US20230227555A1) describes a method for treating, preventing, or alleviating symptoms of a coronavirus infection by administering a composition containing an anti-CD3 antibody. The antibody can be a monoclonal antibody and may be fully human or humanized. The patent also specifies the amino acid sequences of the heavy and light chain complementarity determining regions of the antibody.
The method can be used for treating various symptoms of a coronavirus infection, including hyperactive immune response, fever, gastrointestinal symptoms, respiratory symptoms, loss of smell or taste, cough, headache, and more. It can be applied to subjects who have a confirmed or suspected coronavirus infection, as well as those who have been exposed to the virus but have not yet developed symptoms.
In addition to the anti-CD3 antibody, the patent suggests the administration of dexamethasone, an anti-inflammatory drug. The composition can be administered orally, mucosally, by inhalation, nasally, intravenously, or through a combination of these methods. Inhalation administration can be done using an inhaler or a nebulizer.
The patent also mentions the possibility of administering other antibodies, such as anti-TNFa, anti-CD20, anti-IFN?, anti-Granulocyte-Macrophage Colony-Stimulating Factor, or anti-IL-6R antibodies, along with the anti-CD3 antibody. Additionally, antiviral drugs, immune booster drugs, and vitamins C, D, and E can be administered in combination with the anti-CD3 antibody.
The dosage of the anti-CD3 antibody can vary depending on the administration method. For nasal administration, a daily dose of 50 µg to 100 µg is suggested, while for oral administration, a daily dose of 1.0 to 2.5 mg is recommended. The treatment can be administered for at least 10 consecutive days.
The patent also extends the use of the anti-CD3 antibody to the treatment of other diseases or disorders, such as inflammatory diseases (e.g., autoimmune encephalomyelitis, lupus, arthritis), pulmonary diseases (e.g., acute respiratory distress syndrome), and neurodegenerative diseases (e.g., multiple sclerosis).
Furthermore, the patent describes a method for personalized treatment based on the measurement of a marker for hyperactive immune response. By collecting a sample from the subject and measuring the marker, the level of the anti-CD3 antibody can be determined and administered accordingly.
It is important to note that this summary is based solely on the claims provided in the patent and does not include any additional information or context.
To know more about GlobalData’s detailed insights on Tiziana Life Sciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
